Animal testing is not going to stop on a single date. No global deadline exists, and the most ambitious national targets have already been missed. But the trajectory is clearly toward fewer animals used each year, driven by new laws, better technology, and a growing scientific consensus that animal models often fail to predict what happens in humans. The realistic picture is a gradual phase-out over decades, not a sudden ban.
Why the Timeline Keeps Shifting
The Netherlands made the boldest commitment of any country when it declared in 2016 that it would phase out animal experiments by 2025. That target has not been met. A high number of animal experiments are still performed there, though the Dutch government says its commitment remains. This pattern, ambitious goals followed by delays, reflects a core tension: the desire to stop animal testing runs ahead of the ability to replace it in every context.
No other major country has set a firm end date. The European Union operates under a directive that promotes the “3Rs” framework (replacing, reducing, and refining animal use), but it has not legislated a deadline for elimination. The United States, China, Japan, and other large research economies have no phase-out timeline at all. What exists instead is a patchwork of sector-specific bans and policy shifts that chip away at animal testing one category at a time.
The U.S. Law That Changed the Rules
In December 2022, President Biden signed the FDA Modernization Act 2.0 into law. This was a landmark shift. Since 1938, U.S. law had required animal testing for every new drug seeking FDA approval. The new law removed that mandate, allowing drug companies to use alternative methods like cell-based assays, computer modeling, and organ-on-a-chip technology to demonstrate safety before human trials.
This does not ban animal testing. It makes it optional rather than legally required. Drug companies can still choose to use animals, and many will for the foreseeable future because regulators are familiar with animal data and the alternative methods are still being validated across different drug types. But the law opened a door that had been sealed for over 80 years, and it signals where the regulatory world is heading.
Animal Tests Fail Most of the Time
One of the strongest arguments for moving away from animal testing is that it doesn’t work very well. The FDA estimated in 2004 that 92 percent of drugs passing animal tests go on to fail in human clinical trials. More recent analyses suggest the failure rate has climbed to roughly 96 percent. The main reasons are lack of effectiveness in humans and safety problems that animal tests did not predict.
This isn’t just an ethical issue. It’s a scientific and financial one. Each drug that clears animal testing but fails in humans represents years of development time and hundreds of millions of dollars wasted. That failure rate has become a powerful motivator for pharmaceutical companies to explore alternatives, not out of compassion alone, but because better predictions mean faster, cheaper drug development.
Technologies Replacing Animals
Several technologies are already reducing the number of animals used in research, and their capabilities are expanding rapidly.
AI-driven computer models can now screen drug compounds before any living organism is involved. In cardiovascular research, AI tools that predict heart toxicity risk have reduced exploratory animal studies by 60 to 80 percent for certain applications. Broader modeling approaches combining AI with simulations of how drugs move through the human body could eliminate 50 to 70 percent of exploratory animal studies in well-defined testing scenarios.
Organ-on-a-chip devices, which are small platforms containing living human cells arranged to mimic the function of organs, are showing real promise. A study analyzing 870 liver chips found they outperformed conventional models at predicting drug-induced liver injury, one of the most common reasons drugs fail after reaching the market. These chips replicate human biology more accurately than a mouse liver ever could.
Virtual patient cohorts offer another path forward. In heart valve device development, which traditionally required about 56 sheep over 24 months of iterative testing, researchers can now run design optimization through virtual cohorts of roughly 2,000 digital patients. The animal component drops to a single confirmatory study using about 12 animals. That’s a reduction of nearly 80 percent in a field where animal testing seemed unavoidable.
Where Cosmetics Testing Already Stopped
The cosmetics industry is furthest along. The EU banned animal testing for cosmetic products and ingredients in 2013. India, Israel, South Korea, Australia, and several other countries followed with their own bans. More than 40 countries now restrict or prohibit cosmetic animal testing in some form. This sector proved that viable alternatives exist for skin irritation, eye damage, and allergic reaction testing, categories where cell-based methods can fully replace animals.
Cosmetics were easier to tackle because the products interact mainly with skin and eyes, organs that can be modeled with lab-grown human tissue. Drug development and basic biomedical research involve far more complex questions about how substances affect entire body systems over time, which is why those areas lag behind.
What Still Can’t Be Replaced
The honest obstacle to ending animal testing is that current alternatives cannot replicate everything a living body does. Cells grown in a dish lose their natural shape and stop behaving the way they do inside an organism. They aren’t exposed to blood flow, mechanical stretching, or the hormonal signals that come from neighboring organs. Most critically, no in vitro system can model the interactions between multiple organ systems simultaneously, like how a drug processed by the liver affects the kidneys, which then alters blood chemistry that impacts the brain.
This matters most for systemic toxicity testing: understanding what a substance does to the whole body over weeks or months. Organ-on-a-chip technology is moving toward multi-organ platforms that connect liver, heart, kidney, and lung chips, but these systems are still in development and not yet accepted by regulators as standalone replacements for animal studies in most contexts.
Basic research into complex diseases like Alzheimer’s, cancer metastasis, and autoimmune conditions also relies heavily on animal models. These areas involve whole-body processes that no current technology can fully simulate. Replacement here will likely come last.
A Realistic Timeline
Based on current trends, the phase-out will happen in stages. Cosmetic testing on animals is largely finished in much of the world already and will likely be banned globally within the next decade. Chemical safety testing, which accounts for a large share of animal use, will shift substantially toward computer models and cell-based methods over the next 10 to 15 years as regulatory agencies validate and accept those alternatives.
Drug development will take longer. The FDA Modernization Act 2.0 removed the legal barrier, but practical adoption of alternatives will be gradual. Expect animal use in pharmaceutical testing to decline significantly over the next 15 to 20 years, with the steepest drops in early-stage screening where AI already performs well. Late-stage safety testing and regulatory-required studies will be the last to change.
Basic biomedical research is the hardest category to predict. This is where scientists study fundamental disease processes and biological mechanisms, work that often requires observing effects in living systems. A complete end to animal use in this area is likely decades away, potentially beyond 2050, and depends on breakthroughs in multi-organ simulation technology that don’t yet exist.
The number of animals used in testing worldwide, estimated at over 100 million per year, will continue to fall. But a single date when all animal testing stops everywhere is not on any realistic horizon. What is happening, measurably and accelerating, is a transition where animals go from being the default to being the last resort.